Australia markets closed

ABBV Nov 2022 120.000 put

OPR - OPR Delayed price. Currency in USD
Add to watchlist
1.2000+0.3500 (+41.18%)
At close: 02:19PM EDT
Full screen
Previous close0.8500
Open1.0800
Bid0.9700
Ask1.2600
Strike120.00
Expiry date2022-11-18
Day's range1.0800 - 1.2100
Contract rangeN/A
Volume7
Open interest671
  • Simply Wall St.

    AbbVie Inc.'s (NYSE:ABBV) Business Is Trailing The Market But Its Shares Aren't

    With a price-to-earnings (or "P/E") ratio of 20.1x AbbVie Inc. ( NYSE:ABBV ) may be sending bearish signals at the...

  • Motley Fool

    Is AbbVie a Buy?

    Drugmaker AbbVie (NYSE: ABBV) is one of the largest healthcare stocks in the world, with a market cap of over $250 billion. AbbVie last reported its earnings in July. Humira remains key to AbbVie's business for now, generating $5.4 billion this past quarter, nearly three times the $1.8 billion Skyrizi and Rinvoq generated.

  • Motley Fool

    Got $1,000? 2 Stocks That Could Be Bargain Buys For 2022 and Beyond

    Let's look at two biotech stocks that look attractive at current levels: AbbVie (NYSE: ABBV) and Gilead Sciences (NASDAQ: GILD). AbbVie is one of the largest pharmaceutical companies around. Like other drugmakers, AbbVie benefits from the fact that doctors do not stop prescribing lifesaving drugs even during challenging economic times, nor do patients stop taking them.